Phase 2 Osteoarthritis Trial, Recruiting NCT07161336 Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Condition: Osteoarthritis
Back to Osteoarthritis

Phase 2 Osteoarthritis Trial, Recruiting

NCT07161336
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men and women between 40 and 70 years old
  • People diagnosed with knee osteoarthritis based on established medical criteria, including knee pain plus at least 3 out of a specific set of 4 clinical signs (confirm with trial site for full details)
  • People who have had knee pain on most days for at least 6 months, with pain rated at a meaningful level on a standard pain scale (at least 40mm on a 100mm scale)
  • People whose knee X-rays show a moderate level of osteoarthritis severity (graded 2 or 3 on a standard scale)
  • People whose knee ultrasound scan shows signs of inflammation inside the knee joint

Who may not be able to join:

  • People with any known inflammatory joint disease (such as rheumatoid arthritis)
  • People with a body mass index (a measure of body weight relative to height) of 40 or above
  • People with significantly reduced kidney function, liver problems (including active hepatitis B or C, or abnormal liver results), or certain blood abnormalities (confirm with trial site for specific threshold values)
  • People who have used steroid medications — whether injected into a joint, injected into a muscle, or taken by mouth — within the past 4 weeks
  • People with a history of knee joint surgery or a condition called Charcot joint (a type of severe joint damage)
  • People with a severe inward angling of the knee greater than 30 degrees
  • People who have used certain disease-modifying medications (such as hydroxychloroquine or sulfasalazine) in the past 3 months
  • People with a known allergy to methotrexate (a medication used in this trial)
  • Women who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Shamim Ahmed Professor, FCPS, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Phone: +8801726459070

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Registry
ClinicalTrials.gov
Start date
30 July 2025
Est. completion
1 July 2026

Where this trial is recruiting

Bangladesh

Primary endpoints

To assess the role of Methotrexate to change the functional status with Western Ontario and McMaster Universities Osteoarthritis Index in patients with ultrasound proven synovitis associated with primary knee Osteoarthritis.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov